Drug Profile
Research programme: fibrosis therapeutics - 4D Science/Karo Pharma
Alternative Names: Fibrotic disease therapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator 4D Science; Karo Bio
- Developer 4D Science; Karo Pharma AB
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Fibrosis in Germany
- 04 Nov 2017 No recent reports of development identified for research development in Fibrosis in Sweden
- 23 Sep 2013 Early research in Fibrosis in Germany (unspecified route)